INFANT'S ADVIL (ibuprofen) by GSK is cyclooxygenase inhibitors [moa]. First approved in 1998.
Drug data last refreshed 8h ago · AI intelligence enriched 6d ago
Infant's Advil is an oral ibuprofen suspension/drops formulation approved in 1998 for pediatric use. It is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting cyclooxygenase enzymes to reduce pain, fever, and inflammation. The product is specifically designed for infants and young children who cannot swallow solid dosage forms.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting potential team restructuring and transition focus.
Cyclooxygenase Inhibitors
Nonsteroidal Anti-inflammatory Drug
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Comparative Bioavailability Study of Reformulated Ibuprofen 2% and 4% Oral Suspensions (Berlin Chemie AG) and Versus Ibuprofen (Nurofen®) 200 mg/5 ml Oral Suspension
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Efficacy and Safety of S (+) - Ibuprofen in the Treatment of Mechanical Low Back Pain
Postoperative Analgesic Effects of Ibuprofen Versus Ketorolac in Patients Undergoing in Orthopedic Surgery
Ibuprofen Plus Acetaminophen for Enhanced Pain Reduction
Worked on INFANT'S ADVIL at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Infant's Advil offers exposure to pediatric OTC marketing, pricing pressures, and generic defense strategies in a mature franchise. Career growth is constrained by LOE proximity; professionals should seek roles emphasizing market access innovation, generic transition planning, or parent company portfolio optimization.